[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)]

Clin Calcium. 2016 Feb;26(2):259-67.
[Article in Japanese]

Abstract

CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.

Publication types

  • Review

MeSH terms

  • Bone Diseases, Metabolic / diagnosis
  • Bone Diseases, Metabolic / etiology*
  • Bone Diseases, Metabolic / metabolism
  • Bone Diseases, Metabolic / therapy*
  • Bone and Bones / metabolism*
  • Bone and Bones / pathology
  • Calcimimetic Agents / therapeutic use
  • Calcinosis
  • Calcium Carbonate / therapeutic use
  • Cardiovascular Diseases / etiology
  • Cinacalcet / therapeutic use
  • Ferric Compounds / therapeutic use
  • Fractures, Bone / etiology
  • Humans
  • Minerals / metabolism*
  • Parathyroidectomy
  • Phosphates / metabolism
  • Phosphorus, Dietary / administration & dosage
  • Renal Insufficiency, Chronic / complications*
  • Risk Factors
  • Sevelamer / therapeutic use

Substances

  • Calcimimetic Agents
  • Ferric Compounds
  • Minerals
  • Phosphates
  • Phosphorus, Dietary
  • ferric citrate
  • Sevelamer
  • Calcium Carbonate
  • Cinacalcet